Nucleix Ltd.

Nucleix Ltd. develops, manufactures, and markets non-invasive liquid biopsy cancer detection tests using proprietary epigenetic technology. The company specializes in early detection of cancer through blood and urine-based assays, enabling diagnosis when treatment options are most effective. Primary product is Bladder EpiCheck®, a urine-based test for non-muscle invasive bladder cancer (NMIBC) recurrence monitoring and upper tract urinary cancer detection. Bladder EpiCheck® holds FDA 510(k) clearance in the United States and CE-IVD marking in Europe. Lung EpiCheck® is in clinical development as a blood-based early detection test for high-risk individuals. The EpiCheck platform represents a liquid biopsy technology capable of supporting expansion to additional cancer types. Nucleix collaborates with leading global medical centers, hospitals, and clinical laboratories including Cleveland Clinic, Duke Hospital, Radboud UMC, Vanderbilt University, and numerous European and Israeli institutions. The company operates manufacturing and testing capabilities and maintains R&D competencies for assay development. Distribution extends across North America, Europe, and other international markets through partnerships with hospital systems and reference laboratories.